DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways[1][2][3].
IC50 Target
GLP-1/GIP[1]
体外研究 (In Vitro)
DA-JC4 (1~100 nM; hippocampal cells) inhibits rotenone-induced hippocampal neuron death and significantly suppresses Cyt C, Bax and Caspase activation[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
DA-JC4 (10 nmol/kg; i.p.; once-daily for 14 days) significantly prevents spatial learning deficits in a Y- maze test and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus[1]. DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF)[2]. DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson’s disease symptom potentially and enhances neurotransmission[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Male Sprague-Dawley rats (210–230 g)
Dosage:
10 nmol/kg
Administration:
I.p.
Result:
Significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus.
Animal Model:
Adult male C57BL/6 mice (8 week-old)
Dosage:
25 nmol/kg/day
Administration:
I.p.
Result:
Showed high levels expression of tyrosine Hydroxylase in the s. nigra and increased expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF).
Animal Model:
Adult male Sprague-Dawley (SD) rats (230-280 g)
Dosage:
50 nmol/kg
Administration:
I.p.
Result:
Improved Parkinson’s disease symptom potentially and enhanced neurotransmission.
Room temperature in continental US; may vary elsewhere.
储存方式
Protect from light, stored under nitrogen
Powder
-80deg;C
2 years
-20deg;C
1 year
*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (protect from light, stored under nitrogen)
参考文献
[1]. Shi L, et al. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res. 2017;327:65-74.
[2]. Feng P, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson’s disease. Neuropharmacology. 2018;133:385-394.
[3]. Li T, et al. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson’s disease model. Life Sci. 2020;256:117824.
